Mayo Clinic in Arizona, with one of the most active bone marrow transplant programs in United States, will open its own stem cell laboratory in summer 2014. The laboratory will be initially dedicated to storing and processing stem cells used for bone marrow transplants at Mayo Clinic Hospital and Phoenix Children’s Hospital.Continue reading
Category Archives: AZBio News
Scott Arden Joins Xeridiem® as Product Development Director
Xeridiem has expanded the leadership team with the appointment of Scott Arden as Product Development Director, he has extensive experience in new product development.Continue reading
ASU Spinout HealthTell Raises $4 million in New Funding for Innovative Cancer Tests
AZ-based company developing inexpensive tools for individual health monitoringContinue reading
BioDirection Completes $3.95 Million Series A Financing
Tucson Arizona Company Developing Rapid Point of Care Testing for Mild Traumatic Brain Injury (Concussion)Continue reading
Illumina, Qiagen set to drive adoption of NGS testing for clinical use with new platforms (BioPharm Insight)
- Next-generation sequencing could help find answers behind misunderstood pediatric diseases
- Results are now available within a day or two
- Costs of genomic sequencing have dropped dramatically
Insys Therapeutics on the rise
In the three months since Chandler, Arizona based Insys Therapeutics had its initial public offering Insys stock has been on the rise with a gain of over 120% from its original offering price. Continue reading
Today’s Students;Tomorrow’s Bioscience Leaders
STEM education is one of the hottest topics in education and economics today. To be globally competitive in the future, our nation and our industry needs to encourage and inspire students to pursue STEM careers and to support the teachers who are nurturing our future leaders.Continue reading
Phoenix Children’s get $1M Grant to Fund Cancer Research
Republished with permission from AZ Business MagazineContinue reading
Opportunity Alert: Four NIH SBIR Programs Now Open for Applications
NCI PREVENT Cancer Program
The NCI PREVENT Cancer Program provides resources to move novel cancer-preventive chemical or biological agents and biomarkers towards clinical testing. Through a partnership with NCI, promising chemopreventive agents will be optimized and tested with the goals of filing an Investigational New Drug application with the U.S. FDA and entering the agent into clinical testing. Click here to learn more. The next deadline to apply is October 7, 2013.
NCI NExT Program
The NCI Experimental Therapeutics (NExT) Program consolidates NCI’s anticancer drug discovery and development resources in support of a goal-driven therapeutics pipeline. NCI partners with researchers from industry or academia to facilitate the milestone-driven progression of new anticancer drugs and imaging agents towards clinical evaluation and registration. Click here to learn more. The next deadline to apply is October 15, 2013.
NCI CADP
The NCI Clinical Assay Development Program (CADP) provides resources for clinical assay validation to assist with the development of assays that may predict therapy response or prognostic behavior of a diagnosed cancer, primarily for use in clinical trials. Click here to learn more. The next deadline to apply is October 15, 2013.
NCATS Therapeutics for Rare and Neglected Disease (TRND) Program
The National Center for Advancing Translational Sciences (NCATS) is pleased to announce an open opportunity to submit proposals to collaborate with the Therapeutics for Rare and Neglected Diseases (TRND) program.
The TRND program supports preclinical and early clinical development of new drugs for rare and neglected tropical diseases by establishing collaborative partnerships with external researchers. Intended candidates for collaboration will be researchers who have promising leads and disease/target knowledge, but who lack the expertise or resources to fully develop these projects into clinical stage programs attractive to biopharmaceutical or other suitable organizations. TRND seeks to partner with academic laboratories, not-for-profit organizations, and for-profit companies. Foreign organizations are eligible to apply. TRND provides significant in-kind research support, but no direct external funding is available.Interested applicants may visit TRND on the web to learn more about the program, and can refer to the current NIH Guide Notice for more information.
Interested applicants must contact the TRND Solicitation Coordinator by email (TRND@mail.nih.gov) to initiate a pre-screening / Letter of Intent (LOI) process. Applications are made through the online proposal system, proposalCENTRAL (https://proposalcentral.altum.com/).
LOIs must be completed no later than September 16, 2013. Final applications are due by September 30, 2013.